Lisa Kohler, MD - AkronCantonMDNews

More documents

Recommendations

Info

FDA Approves Second-Generation Smallpox Vaccine The U.S. Food and Drug Administration has licensed a new vaccine to protect against smallpox, a highly contagious disease with the potential to be used as a deadly bioterror weapon. The vaccine, ACAM2000, is intended for the inoculation of people at high risk of exposure to smallpox and could be used to protect individuals and populations during a bioterrorist attack. It will be included in the Centers for Disease Control and Prevention’s (CDC) Strategic National Stockpile of medical supplies. A worldwide vaccination program eradicated smallpox in the population. The last case of naturally occurring smallpox in the U.S. was in 1949 and the last case in the world was reported in Somalia in 1977. Known stockpiles of the virus are kept in only two approved labs in the United States and Russia. The CDC considers it a category A agent, meaning it presents one of the greatest potential threats for harming public health. Smallpox is caused by the variola virus, a virus that emerged in human populations thousands of years ago. It spreads through close contact with infected individuals or contaminated objects, such as bedding or clothing. There is no FDA-approved treatment for smallpox and the only prevention is vaccination. “The licensure of ACAM2000 supplements our current supply of smallpox vaccine, meaning we are more prepared to protect the population should the virus ever be used as a weapon,” said Jesse L. Goodman, M.D., MPH, Director of FDA’s Center for Biologics Evaluation and Research. “This vaccine is manufactured using modern cell-culture technology, allowing rapid and large-scale production of a vaccine with consistent product quality.” The symptoms of smallpox typically began with high fever, headaches and body aches. A rash followed that spread and progressed to raised bumps and pus-filled blisters that crusted, scabbed and fell off after about three weeks, leaving a pitted scar. The fatality rate historically was about 30%, according to the CDC. ACAM2000 is made using a poxvirus called vaccinia, which is related to but different from the virus that causes smallpox. The vaccine contains live vaccinia virus and works by causing a mild infection that stimulates an immune response that effectively protects against smallpox without actually causing the disease. The vaccine is derived from the only other smallpox vaccine licensed by FDA, Dryvax, approved in 1931 and now in limited supply because it is no longer manufactured. Although smallpox vaccination ended in the United States in 1972 because it was no longer needed for prevention, the U.S. military resumed vaccination of at-risk personnel in 1999 after concluding that the disease posed a potential bioterrorism threat. “Smallpox could be a particularly dangerous biological threat to us that would kill or debilitate a high percentage of the population,” said Rear Adm. W. Craig Vanderwagen, M.D., Assistant Secretary for Preparedness and Response, U.S. Department of Health & Human Services. “The licensing of ACAM2000 will make us better prepared as a nation because it provides an important, effective tool for protecting first responders and individuals with a high risk of exposure from this potentially lethal disease.” ACAM2000 was studied in two populations: those who had never been vaccinated for smallpox and those who had received smallpox vaccination many years earlier. current topics The percentage of unvaccinated persons who developed a successful immunization reaction was similar to that of Dryvax. ACAM2000 also was found to be acceptable as a booster in those previously vaccinated for smallpox. Because ACAM2000 contains live vaccinia virus, care must be taken to prevent the virus from spreading from the inoculation site to other parts of the body and to other individuals. To minimize known risks, the vaccine licensing is subject to a risk minimization action plan (RiskMAP). The RiskMAP requires providers of the vaccine and patients to be educated about these and other risks. The RiskMAP also requires patient education through an FDA-approved medication guide for those who receive the vaccine. The medication guide explains the proper care of the vaccination site and provides information about serious side effects that can occur with ACAM2000. In studies, about one in 175 healthy adults who received smallpox vaccine for the first time developed inflammation and swelling of the heart and/or surrounding tissues (myocarditis and/or pericarditis). Of the 10 affected adults, four had no symptoms and at the end of the study, all but one had their symptoms resolve. ACA M20 0 0 is manufactured by Acambis Inc. of Cambridge, England, and Cambridge, MA. Dryvax was made by Wyeth Laboratories Inc. based in Madison, NJ. See Also: IDSA Bioterrorism Information and Resources: www.idsociety.org/bt/toc.htm www.cidrap.umn.edu/idsa/bt/smallpox/biofacts/smllpx-summary.html ■ Source: Infectious Disease Society of America 2 6 | GREATER AKRON/CANTON M.D. NEWS JANUARY-FEBRUARY 2008
M.D. NEWS 2008 ANNUAL DIRECTORY FOR PHYSICIANS Greater Akron/Canton Edition Directory Index Business & Lifestyle Products/Services Accounting Services Advertising/Public Relations Architects Banking Services Billing & Collection Building/Renovating Continuing Medical Education Financial Planning Insurance Legal Services Printing Services Healthcare & Related Services Behavioral/Mental Health Care Cancer Centers Cardiac Care Laboratory Services Neurology/Neurosurgery Orthotics & Prosthetics Physician Referral Lines Senior Healthcare Services Stroke Care Vascular Surgery Weight Loss Surgery Wound Care Centers www.akroncantonmdnews.com
Page 1: Greater Akron/Canton Edition | Janu
Page 4 and 5: contents VOL. 12, NO. 1 JANUARY-FEB
Page 6 and 7: cover story Lisa Kohler, MD Dealing
Page 8: PHOTO © SMITHBERGER PHOTOGRAPHY, N
Page 11 and 12: Akron General Health System and Cle
Page 13 and 14: surgery feature Bariatric Surgery a
Page 15 and 16: ypass; the other group was a commun
Page 17 and 18: Home Medical Equipment and Supplies
Page 19 and 20: feature Obesity: The Continued Batt
Page 22 and 23: esearch NEW STUDY EXAMINES BRAIN-GU
Page 24 and 25: AFFINITY MEDICAL CENTER APPOINTS IN
Page 26 and 27: Northeast Ohio Quality Improvement
Page 30 and 31: Business & Lifestyle ACCOUNTING SER
Page 32 and 33: EMERGENCY DEPARTMENTS HOME HEALTH C
Page 34 and 35: LABORATORY SERVICES MINIMALLY INVAS
Page 36 and 37: REHAB - OUTPATIENT cont. SPORTS MED
Page 38 and 39: Kiddie Tax Changes in 2008 By Micha
Page 40 and 41: hospital spotlight Akron General’
Page 42 and 43: 4 0 | GREATER AKRON/CANTON M.D. NEW
Page 44 and 45: ■ 4 2 | GREATER AKRON/CANT
Page 46: cardiology Doctors Report Rare Hear
Page 49 and 50: Key Elements in Developing a Websit
Page 51 and 52: them as tending to “disrupt conti
Page 53 and 54: the sommelier Some Like It Hot By N
Page 55 and 56: GREATER AKRON/CANTON M.D. NEWS JANU
Page 57 and 58: PQRI: You Can Pry a Few More Bucks
Page 59 and 60: PEER-REVIEWED, ONLINE DATABASE SHOW
Page 61 and 62: What’s New at Area Hospitals hosp
Page 63 and 64: The new and expanded Center for Ort

Lisa Kohler, MD - AkronCantonMDNews

Create successful ePaper yourself

Delete template?

Save as template?